Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a preliminary report
Flávia de Lima Osório, Rafael Faria Sanches, Ligia Ribeiro Horta de Macedo, Rafael G. Dos Santos, João Paulo Maia‐de‐oliveira, Lauro Wichert‐ana, Dráulio Barros de Araújo, Jordi Riba, José Alexandre S. Crippa, Jaime E. C. Hallak
Brazilian Journal of Psychiatry March 1, 2015 DOI: 10.1590/1516-4446-2014-1496 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Observational study Peer reviewed |
|---|---|
| Population | Patients with a depressive disorder |
| Intervention | Ayahuasca |
| Topics | Anxiety Ayahuasca Depression |
| Keywords | Hypomania Antidepressant Mood Depression economics Rating scale Bipolar disorder Clinical psychology Psychosis |
| Citations | 486 |
| Key findings | Ayahuasca has fast-acting anxiolytic and antidepressant effects in patients with a depressive disorder. |
Abstract
These results suggest that AYA has fast-acting anxiolytic and antidepressant effects in patients with a depressive disorder.
In the evidence
This study is part of the evidence base for 3 syntheses in the library. Here is how each one recorded it.
-
Ayahuasca showed fast-acting anxiolytic and antidepressant effects in patients with a depressive disorder.
Synthesized
-
Ayahuasca showed fast-acting anxiolytic and antidepressant effects in patients with a depressive disorder.
Synthesized
-
State of the evidence: Ayahuasca Supports
Reports that ayahuasca has fast-acting anxiolytic and antidepressant effects in patients with a depressive disorder.
Synthesized
Comparable studies
Other observational and cohort studies on ayahuasca for depression, most cited first.
Citations in the library
Cited by 408
- Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial Journal of Psychopharmacology November 30, 2016
- Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. The Lancet Psychiatry May 17, 2016
- REBUS and the Anarchic Brain: Toward a Unified Model of the Brain Action of Psychedelics Pharmacological Reviews June 20, 2019
- Psychedelics Promote Structural and Functional Neural Plasticity Cell Reports June 1, 2018
- Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology November 8, 2017
and 403 more in the library
Cites 13
- Human hallucinogen research: guidelines for safety. Journal of Psychopharmacology July 1, 2008
- Human Pharmacology of Ayahuasca: Subjective and Cardiovascular Effects, Monoamine Metabolite Excretion, and Pharmacokinetics Journal of Pharmacology and Experimental Therapeutics June 18, 2003
- Personality, Psychopathology, Life Attitudes and Neuropsychological Performance among Ritual Users of Ayahuasca: A Longitudinal Study PLoS One August 8, 2012
- Subjective effects and tolerability of the South American psychoactive beverage Ayahuasca in healthy volunteers Psychopharmacology February 22, 2001
- Increased frontal and paralimbic activation following ayahuasca, the pan-amazonian inebriant Psychopharmacology March 30, 2006
and 8 more in the library